Imugene with Proactive at ASX Small and Mid Cap Conference
Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO and managing director Leslie Chong chats with Proactive's Jonathan Jackson live from the ASX Small and Mid Cap...
Stay updated with breaking news from Imugene Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO and managing director Leslie Chong chats with Proactive's Jonathan Jackson live from the ASX Small and Mid Cap...
The trial will be available for just 44 patients around the world. After the trial finishes, the vaccine will either be licensed for use or if it's successful, a bigger study will be carried out.
UK News: A British Indian doctor is the chief investigator of a "ground-breaking" trial of a vaccine to treat early bowel cancer for patients worldwide, follow
The treatment will trialled at the Royal Surrey NHS Foundation Trust and Queen Elizabeth Hospital in Adelaide.
Imugene Ltd (ASX:IMU, OTC:IUGNF) and NeoImmuneTech Inc, a T-cell-focused, US-based biopharmaceutical firm, have announced a strategic partnership to explore...